Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Erythropoietin.

A J Erslev1

  • 1Cardeza Foundation, Thomas Jefferson University, Philadelphia, PA 19107.

Leukemia Research
|January 1, 1990
PubMed
Summary

Erythropoietin, a kidney hormone, stimulates red blood cell production. Recombinant erythropoietin effectively treats anemia in chronic kidney disease and premature infants, with future potential for bone marrow failure.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Erythropoietin and anemia of cancer.

European journal of haematology·2000
Same author

Platelet kinetics in autosomal dominant macrothrombocytopenia.

The Journal of laboratory and clinical medicine·1998
Same author

Clinical erythrokinetics: a critical review.

Blood reviews·1997
Same author

Erythropoietin in the pathogenesis and treatment of the anemia of chronic renal failure.

Kidney international·1997
Same author

Pure red-cell aplasia: a review.

Blood reviews·1996
Same author

Compensated hemolytic anemia.

Blood·1995

Area of Science:

  • Nephrology
  • Hematology
  • Biotechnology

Background:

  • Bone marrow compensates for blood loss and hypoxia via a renal hormone, erythropoietin.
  • Erythropoietin is produced by renal peritubular interstitial cells in response to hypoxia.
  • Molecular engineering enables large-scale in vitro production of recombinant erythropoietin.

Purpose of the Study:

  • To investigate the therapeutic potential of recombinant erythropoietin.
  • To evaluate its efficacy in treating anemia associated with chronic kidney disease and prematurity.
  • To explore its future applications in managing anemia in bone marrow failure.

Main Methods:

  • Utilized molecular engineering for recombinant erythropoietin production.
  • Administered recombinant erythropoietin as a replacement hormone therapy.
  • Clinical evaluation of patient response and anemia markers.

Main Results:

  • Recombinant erythropoietin successfully improved or eliminated anemia in patients with chronic kidney disease.
  • Treatment with recombinant erythropoietin was effective in addressing anemia of prematurity.
  • Demonstrated the potential for transfusion independence in treated patients.

Conclusions:

  • Erythropoietin is a key regulator of erythropoiesis, mediated by the kidneys.
  • Recombinant erythropoietin is a viable therapeutic agent for specific types of anemia.
  • Future research may expand its use to bone marrow failure anemias, potentially eliminating transfusion dependence.

Related Experiment Videos